Capricor Therapeutics (NASDAQ:CAPR) Trading Down 2.5% – Here’s Why

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) dropped 2.5% during trading on Wednesday . The company traded as low as $20.72 and last traded at $21.05. Approximately 431,408 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 1,095,667 shares. The stock had previously closed at $21.60.

Analyst Ratings Changes

CAPR has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 price target on shares of Capricor Therapeutics in a research note on Friday, September 20th. Maxim Group lifted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $22.60.

Capricor Therapeutics Stock Down 9.8 %

The company has a market cap of $591.29 million, a PE ratio of -21.25 and a beta of 4.01. The business’s fifty day moving average is $8.74 and its 200-day moving average is $6.45.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Analysts forecast that Capricor Therapeutics Inc will post -1.13 EPS for the current fiscal year.

Insider Buying and Selling at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the stock in a transaction on Friday, September 20th. The shares were acquired at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the acquisition, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in CAPR. BNP Paribas Financial Markets purchased a new position in Capricor Therapeutics during the first quarter valued at approximately $40,000. Vanguard Group Inc. lifted its holdings in shares of Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after buying an additional 200,499 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics in the second quarter worth $147,000. Finally, Main Street Financial Solutions LLC lifted its holdings in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after buying an additional 7,500 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.